Innovations in Small Interfering RNA (siRNA) Therapy
HCPLive
MAY 8, 2024
Leading experts highlight the established role of PCSK9 inhibitors, such as evolocumab and alirocumab, and introduce the promising second-generation PCSK9 inhibitors, known as small interfering RNA (siRNA), which represent an innovative therapeutic approach that selectively reduces the production of specific proteins through RNA interference.
Let's personalize your content